Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP), unveiled the new name and new industrial design for its non-invasive and painless test for the early detection of cervical precancer. LuViva™ will be on display at The American College of Obstetricians and Gynecologists (ACOG) Clinical Meeting in Washington, D.C. through May 4, 2011 in Washington, D.C.
"We believe that the new name and new design reflect the exciting and advanced nature of the technology and will appeal to women and healthcare professionals around the world," said Mark L. Faupel, Ph.D., CEO and President of Guided Therapeutics, Inc. "We invite everyone to view the new design and logo on our web site at www.guidedinc.com."
LuViva™ Advanced Cervical Scan is the full name for the new cart design. The name for the single-use calibration and patient interface is the LuViva Cervical Guide. Guided Therapeutics and LuViva™ are located at booth 621.
As previously announced, Dr. Leo B. Twiggs, professor in the Department of Obstetrics and Gynecology at the University of Miami, Miller School of Medicine, is scheduled to present Study Results of a New Test for Cervical Dysplasia: Potential Impact on Patient Management, at ACOG on May 2nd from 2 p.m. to 4 p.m.
The technology, which consists of a base unit and single-patient-use calibration disposable, scans the cervix with light to identify cancer and pre-cancer painlessly and non-invasively. Guided Therapeutics' patented biophotonic technology is able to distinguish between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the Guided Therapeutics test does not require laboratory analysis or a tissue sample, is designed to provide results immediately and eliminate costly unnecessary testing.
The technology is currently under U.S. Food and Drug Administration premarket approval review. In January 2011, Guided Therapeutics was awarded ISO 13485 certification for its quality system, a precursor for the CE mark required for sales in the European Union.
Overtreatment of older men with prostate cancer raises concerns